Effect of Moxonidine on Putative Sympathetic Neurons in the Rostral Ventrolateral Medulla of the Rat

Antonio R. Granata

Department of Psychiatry and Physiology, New York Medical College, Valhalla, N.Y., USA

Key Words
Rostral ventrolateral medulla · Antihypertensive drugs · Intracellular recording · Sympathetic premotor neurons · Imidazoline receptors · $\alpha_2$-Adrenergic receptors

Abstract
We used an intracellular recording technique in vitro to investigate the effects of moxonidine on neurons in the rostral ventrolateral medulla (RVLM) with electrophysiological properties similar to premotor sympathetic neurons in vivo. These neurons were classified as firing regularly and irregularly, according to previous reports. Moxonidine is a sympatho-inhibitory and antihypertensive agent that is thought to be a ligand of $\alpha_2$-adrenergic receptors and imidazoline type-1 receptors in the RVLM. Moxonidine (2–10 $\mu$M) was applied to the perfusate on 4 irregularly firing neurons, and 2 regularly firing neurons. Moxonidine (2 $\mu$M) produced only minor depolarization in 2 of these neurons. However, on 4 tested neurons, moxonidine (10 $\mu$M) elicited a profound inhibitory effect with hyperpolarization (near −20 mV); these neurons practically ceased firing. These changes were partially reversible. The results would indicate that neurons in the RVLM, recorded in vitro and with similar electrophysiological characteristics to a group of neurons previously identified in vivo in the same bulbar region as barosensitive premotor sympathetic neurons, can be modulated by imidazoline-derivative adrenergic agonists. These results could help to understand the hypotensive effects of moxonidine.

Introduction
The rostral ventrolateral medulla (RVLM) is critically involved in the central control of cardiovascular sympathetic activity; additionally, bulbospinal neurons in this area establish the level of excitability of sympathetic preganglionic neurons in the intermediolateral column and in the lamina X of the spinal cord. The spontaneous firing pattern of cardiovascular sympathetic premotor neurons in the RVLM, studied with intracellular recording techniques in vivo [1, 2], is similar to that of isolated sympathetic vasomotor efferent fibers related to the cardiac cycle [3]. Overall, these groups of medullospinal neurons in the RVLM are accepted as the vasomotor efferent projection of the medulla, and perform as premotor sympathetic vasomotor neurons.

There is experimental evidence supporting the existence of at least two different types of barosensitive premotor sympathetic RVLM neurons with projections to the spinal cord. First, a group of neurons fire spontaneous action potentials with a very regular pattern in vitro [4–6] and in vivo during pronounced hypotension [1], and
receive inhibitory postsynaptic potentials synchronized to the cardiac cycle during normal arterial blood pressure [1, 2]. Second, a different group of neurons fire in an irregular mode and receive excitatory postsynaptic potentials locked to the cardiac cycle. These neurons are hyperpolarized by systemic increases in blood pressure or aortic nerve stimulation [1, 2].

It is well known that adrenergic mechanisms are involved in the central control of cardiovascular function [7]. Moreover, the RVLM is the site of action of different pharmacological agents that affect catecholaminergic transmission [8], and are used to treat human vascular hypertension; for example the α2-adrenergic agonist clonidine [9, 10]. Accordingly, pharmacological studies have demonstrated that intraparenchymal injections of adrenergic agonists into the RVLM in vivo activate different subtypes of α-adrenergic receptors and probably β-adrenergic receptors, eliciting either a decrease or an increase in arterial blood pressure and sympathetic nerve activity, respectively [11, 12].

Moreover, different adrenergic agonists applied in vitro to a medullary slice preparation containing the RVLM produced substantial changes in electrophysiological parameters on putative sympathetic neurons [13–15]. Hence, bulbospinal barosensitive neurons in the RVLM are thought to be the sites of action of adrenergic agents mediating central sympathoinhibitory responses [for review, see 16]. For this reason, different investigators have studied the effect of adrenergic agents upon premotor sympathetic neurons in the RVLM in vivo, and on putative RVLM sympathetic neurons in vitro [13, 17, 18].

The pharmacological mechanism involved in the sympathoinhibitory effect in the RVLM of adrenergic agonists with an imidazoline molecular structure is still a matter of discussion. Some investigators support the idea that these drugs inhibit central sympathetic activity by activating α2-adrenergic receptors [19]. On the other hand, for some imidazoline-related drugs, like moxonidine, that are effective for treating different forms of the hypertensive syndrome [10, 20, 21], it was proposed that they mediate their central sympatholytic effect by activating α2-adrenergic receptors [19]. On the other hand, for some imidazoline-related drugs, like moxonidine, that are effective for treating different forms of the hypertensive syndrome [10, 20, 21], it was proposed that they mediate their central sympatholytic effect by activating imidazoline receptors in the RVLM [22, 23], and therefore reduce central sympathetic tonic activity [10, 24]. However, the mechanism of action and in particular the type(s) of neurons in the RVLM targeted by this drug are still unclear.

The aim of this study is to investigate in vitro the effect of moxonidine on RVLM neurons with similar electrophysiological properties to those neurons in the RVLM characterized in vivo as barosensitive and sympathoexcitatory [1, 2]. The characterization of sympathoexcitatory neurons in slice preparations is difficult because of the absence of barosensory inputs and the impracticality of correlating the neuronal activity of these neurons with the sympathetic outflow. Nevertheless, as explained in previous publications [13, 25], we characterized putative sympathoexcitatory neurons according to electrophysiological properties similar to those recorded and characterized in vivo as sympathetic premotor neurons in the RVLM. For this purpose, we recorded intracellularly in vitro from neurons located in a coronal medullary slice preparation that included the RVLM.

**Methods**

The experiments were done on male Sprague-Dawley rats (90–120 g) anesthetized with ether and decapitated. The brain was rapidly removed from the skull and placed in a dish containing Ringer solution (4 ºC) equilibrated with 95% O2 and 5% CO2. The composition of the Ringer solution was (mM): 124 NaCl; 5.0 KCl; 1.3 MgSO4; 1.25 KH2PO4; 2.0 CaCl2; 26 NaHCO3, and 10.0 D-glucose. The medulla with the caudal part of the pons was dissected and fixed with 4% (w/v) paraformaldehyde in a vibratome (Oxford Instruments). The chamber was filled with cold (4 ºC) oxygenated Ringer solution. The medulla was cut into 400- to 500-μm coronal slices containing the RVLM. After that, the slice sections were transferred to an incubation chamber (Medical Systems Co.) and kept in oxygenated Ringer solution at 25–27 ºC for about 1 h. Thereafter, one slice was transferred to a recording chamber (Medical Systems Co.), in which the bottom surface of the slice was placed on filter paper held in place upon the fine nylon mesh of the chamber which was continuously superfused with oxygenated Ringer solution at a rate of 0.3–1.0 ml/min at 34 ± 1 ºC.

Intracellular recordings were obtained with microelectrodes made from borosilicate filamented glass capillary tubing (2.0 mm OD), and filled with a solution of 4–6% biocytin (Sigma) in 0.05 M of KCl or K-acetate (pH 7.0–7.6). Electrode resistances were 110–200 MΩ. Intracellular potentials were recorded in a conventional method described in a previous publication [25] from neurons located between the rostral pole of the RVLM and a plane 500 μm caudally.

**Current Application**

During the recording of the continuous data, there were discontinuous applications of trains (repetition rate 0.5–1.0 Hz) of depolarizing or hyperpolarizing current pulses (380 ms pulse duration) with different intensity levels. The neuronal membrane input resistance was calculated from the magnitude of intracellular hyperpolarizing and depolarizing current pulses, and the corresponding changes in membrane potentials which produced the current/voltage relationship.

**Identification of the Recorded Neurons**

Some of the recorded neurons were intracellularly labelled with biocytin (n = 6) by injecting 4–8 nA negative rectangular pulses of 150 ms duration at 3.3 Hz for 6–10 min. The slice containing the

recorded and injected neuron(s) was transferred to a fixative solution of 4% paraformaldehyde and 1.5% picric acid in phosphate-buffered saline at pH 7.4, and stored at 4°C overnight. After that, the slice was moved to a solution of 30% sucrose in 0.15 M phosphate-buffered saline for 4 h, and then sectioned on a freezing microtome into 50-μm-thick sections which were next rinsed several times in 0.1 M phosphate buffer (pH 7.4) and treated for histofluorescence in the intracellulary labelled neuron(s). Histological sections were incubated for 4 h in avidin-Texas Red 1:200 in phosphate buffer solution plus 0.1% Triton X-100 and 1% sodium azide. At the end of the incubation period, the tissue was rinsed several times in a fresh solution of phosphate buffer for 1 h and the sections were mounted in a solution of glycerol in phosphate buffer (1:3) plus 1% n-propylgallate. Sections were studied under an epifluorescence microscope with a filter combination for rhodamine (G-2A). The position of a filled neuron was determined and marked on a page from a histological atlas [26].

Drug Administration

Moxonidine (2–10 μM) was dissolved in Ringer solution which was applied by a gravity perfusion system.

Results

Fifteen neurons lying within the RVLM from 4 rats were recorded intracellularly. These neurons had resting membrane potentials that varied from −49 to −82 mV, and they were able to generate action potentials with amplitudes larger than 55 mV. The membrane input resistance determined by intracellular current injections ranged from 73 to 150 MΩ.

The recorded neurons were classified as firing regularly and irregularly according to the properties explained in detail in previous publications [13, 25], and similar to those sympathetic premotor neurons characterized in vivo as firing regularly and irregularly [1], and regular and irregular sympathetic premotor neurons reported by Oshima et al. [5]. Accordingly, these neurons were divided into a group of 6 neurons firing in a regular mode (R-type), and another group of 9 neurons firing in an irregular mode (I-type). The recorded neurons were localized in the RVLM, either by intracellular injection of biocytin and searching for the avidin-Texas Red reaction, or by visual recognition of the recording site under microscope.

We tested the effect of moxonidine (2–10 μM) applied to the perfusate while recording intracellularly from 6 neurons located in the RVLM, 2 of them classified as R-type, and 4 as I-type.

In 2 neurons, 1 of them characterized as R-type and the other as I-type, moxonidine (2 μM) produced very minor changes in neuronal activity. The result of one experiment done in a I-type neuron (control recordings in fig. 1A1, A2) shows that 6 min after application of the drug the neuron was slightly depolarized, and the frequency of discharge increased from 11 to 18 Hz (fig. 1B). These minor changes were still present after 15 min of drug perfusion (fig. 1C). The level of depolarization in these neurons was 5–8 mV. These changes were reversible after washing the drug out, as shown in figure 1D1 and D2. No change in the action potential duration or shape was noted after exposing these neurons to this concentration of moxonidine.

On the other hand, a higher concentration of moxonidine (10 μM) elicited very appreciable changes in the neuronal activity of 3 I-type neurons and 1 R-type neuron. As shown in figure 2B, 4 min after application of the drug to the perfusate, (1) a depolarizing effect on membrane potential and (2) a 10–15% increase in membrane input resistance were seen, and (3) the pattern of discharge became very irregular with periods of bursting. However, 24 min after perfusion of the drug (fig. 2C), the membrane potential suffered a dramatic change consisting of marked hyperpolarization (−15 to −20 mV from control). In addition, the input membrane resistance remained increased and the neuron practically ceased firing. These changes were partially reversible; 16 min after washout with normal Ringer solution the membrane potential started to recover, and the neuron was firing in a very irregular pattern. However, the action potential amplitude and shape did not recover during the time period of continued intracellular recording (>20 min), denoting some extra effect of the drug which is difficult to determine at this point.

Discussion

Imidazoline derivatives, like clonidine and moxonidine, are used to treat different types of hypertension [20]. It is accepted that moxonidine is a centrally acting drug and the main site of action is the RVLM [16]. Injections of moxonidine into the RVLM reduce blood pressure and heart rate, and this effect is blocked by the imidazoline type-1 receptor-blocker efaxoxan [20]. However, little is known about the identity of the RVLM neuron(s) involved in the antihypertensive and sympathoinhibitory effect of drugs like moxonidine. It is still controversial whether α2-adrenergic receptors are also activated by moxonidine, or a combination of both imidazoline type-1 and α2-adrenergic receptors could mediate the actions of moxonidine in the RVLM [23].

The present results demonstrate an inhibitory hyperpolarizing effect of moxonidine at concentrations of 10 μM on RVLM neurons with electrophysiological prop-

Moxonidine on Rat RVLM Neurons
Fig. 1. Intracellular recording of an irregularly firing RVLM neuron from an in vitro slice preparation. The records show the time course of effects of the imidazoline-derivative moxonidine (2 μM) perfusion on this neuron. A2, D1 The upper trace is the membrane potential recording which shows the deflections produced by pulses of hyperpolarizing current, and the lower trace shows the magnitude of the injection current. A1, A2 Control: recording before moxonidine (MXD) perfusion.

A1, A2 Control: recording before moxonidine (MXD) perfusion.

B MXD (I): recording starts 6 min after perfusion onset. The membrane potential became slightly more depolarized.

C MXD (II): recording starts 15.6 min after perfusion onset. The membrane potential remained slightly more depolarized, and the firing rate was somewhat increased.

D1–D2 Washout: recording starts 11 min after washout of moxonidine. The membrane potential was hyperpolarized. However, the firing rate was decreased, but it did not recover to control levels. D2 started 2 min after the end of D1.
Fig. 2. Intracellular recording of another irregularly firing RVLM neuron from an in vitro slice preparation. The records show the time course of effects of moxonidine (10 μM) perfusion on this neuron. The upper trace is the membrane potential recording which shows the deflections produced by pulses of hyperpolarizing current, and the lower trace shows the magnitude of the injection current. A Control: recording before moxonidine (MXD) perfusion. B MXD (I): recording starts 4 min after perfusion onset. The membrane potential became more depolarized, and an irregular firing with bursting periods was noted. The input resistance was increased. C MXD (II): recording starts 24 min after perfusion onset. The membrane potential was now notably hyperpolarized, and the firing rate was decreased. The input resistance remained increased. D Washout: recording starts 16 min after washout of moxonidine. The membrane potential had recovered to control levels, and the firing rate was increased, but the spike amplitude was notably reduced.

In the present study we tested the inhibitory effect of moxonidine on both regularly and irregularly firing neurons. Therefore, it is possible to speculate that moxonidine injected in vivo could produce sympathoinhibitory and hypotensive effects, at least in part by inhibiting those sympahtoexcitatory neurons in the RVLM. However, it is important to note the limitations of the in vitro slice preparations to characterize premotor sympathetic neurons, so it is difficult to determine the real number of premotor sympathetic neurons recorded in this study.

The present results still do not resolve the question of what type of receptor mediates this inhibitory response. As we mentioned, both α2-adrenergic and imidazoline type-1 receptors are postulated as the targets of the sympathoinhibitory effect of drugs like moxonidine [16].
Neuroanatomical and pharmacological studies have demonstrated that \( \alpha_2 \)-adrenergic and \( \beta \)-adrenergic receptors are present in high density in neurons in the RVLM [27, 28]. These receptors are functional because, first, local application of different \( \alpha_1 \) and \( \beta \)-adrenergic agonists into the RVLM produced significant changes in arterial blood pressure, heart rate and sympathetic nerve activity [8, 12]. The results of those investigations suggested that catecholamines, in particular adrenaline and noradrenaline, could play a role as neurotransmitters of neurons involved in cardiovascular sympathetic regulation in the RVLM.

In addition, the RVLM is also endowed with imidazoline type-1 receptors, which are proposed as being responsible for mediating the central hypotensive effect of moxonidine [29]. However, this hypothesis is not supported by the experiments reported by Hayar and Guyenet [30] showing that: (1) moxonidine, at concentrations similar to those used in the present study, produced a consistent inhibitory effect on different types of RVLM neurons recorded in an in vitro slice preparation, and this effect is due in part to postsynaptic hyperpolarization; (2) the inhibitory effects of moxonidine were substantially blocked by the selective antagonist of \( \alpha_2 \)-adrenergic receptors SKF 86466, while on the other hand, the imidazoline type-1 antagonist AGN 192403 was ineffective in changing neuronal activity, and (3) the inhibitory effects of moxonidine characterized at pre- and postsynaptic levels are similar to those generated by norepinephrine and other \( \alpha_2 \)-adrenergic agonists on putative presympathetic RVLM neurons. Similar results were reported by Szabo et al. [31] in experiments performed on the rat locus coeruleus neurons in vitro. Further support for the idea that the central sympathoinhibitory effect of drugs like clonidine (imidazoline derivative) is mediated by stimulation of \( \alpha_2 \)-adrenergic receptors is provided by gene substitution experiments in the mouse. The replacement of only one amino acid of the \( \alpha_2A \)-adrenergic receptor subtype produced a strain of mice with a remarkable downregulation in expression of \( \alpha_2A \)-adrenergic receptors [32, 33]. These mutated mice lacked the hypotensive response to systemic injections of clonidine and other \( \alpha_2 \)-adrenergic agonists.

However, Tolentino-Silva et al. [29] have published contradictory results. They demonstrated that: (1) microinjections of moxonidine directly into the sympathoexcitatory area in the mouse RVLM elicited a reduction in blood pressure at concentrations substantially lower than that needed to produce hypotension by systemic administration; (2) imidazoline type-1 receptors are present in the mouse RVLM in higher densities than the rat, and those receptors are solely necessary to mediate the hypotensive responses to moxonidine, and (3) the hypotensive effects of moxonidine tested in transgenic mice deficient in \( \alpha_2A \)-adrenergic receptors were blocked with the selective imidazoline type-1 receptor antagonist efaxoxan.

The present results show that moxonidine reproduces some of the effects of tyramine on putative sympathetic RVLM neurons as demonstrated in a previous publication [34]. However, the shorter latency depolarizing effects of tyramine and moxonidine that in the first case have been ascribed to activation of \( \beta \)-adrenergic receptors in the RVLM [14] could hardly be attributed to moxonidine. Indeed, there is no evidence that moxonidine is a \( \beta \)-adrenergic agonist. However, it is still possible to infer that the transient excitatory effect of moxonidine could have been mediated by the evoked release of endogenous catechols from terminals synapsing on the recorded neuron.

Concerning the ensuing hyperpolarizing effect, the question remains whether moxonidine and the endogenous catecholaminergic transmitter released by tyramine act on the same population of \( \alpha_2 \)-adrenergic receptors. The current results demonstrate some similarities in the mode of action of both tyramine and moxonidine. However, it is still premature to advance any conclusion on this matter.

In conclusion, these results show that moxonidine (10 \( \mu M \)) exerts a hyperpolarizing inhibitory effect on putative sympathetic neurons in the RVLM recorded in an in vitro slice preparation, and using a conventional intracellular recording technique. These results are in agreement with previous studies performed in brain stem slices of neonatal rats [30]. Nevertheless, in that study the authors used either an extracellular recording technique or a whole cell recording technique to study putative premotor sympathetic neurons which were identified mainly as retrogradely labeled RVLM bulbospinal neurons [30]. In our present study putative premotor sympathetic neurons were identified by their electrophysiological characteristics, as described in previous publications [13, 25].

Acknowledgements

This work was supported by a grant from the National Institutes of Health, Heart, Lung, and Blood Institute (HL-56733). Moxonidine was generously supplied by Dr. Paul Ernsberger.
References


Moxonidine on Rat RVLM Neurons


247